Dyesol Continuing to Shore Up Leadership Credentials in the Alternative Energy Sector

With the United Nations predicting global investments of $US15 to $20 trillion will be needed over the next 20 - 25 years to move the world from a conventional to a sustainable energy path, Dyesol Limited (DYE) is continuing to shore up its leadership credentials in the burgeoning alternative energy sector.

This month alone board members and senior scientists will speak at key industry conferences in Japan, Egypt and Melbourne, Australia.

Managing director Mrs Sylvia Tulloch will deliver a keynote speech on 3rd generation Photovoltaics - The business case for DSC” at the International Photovoltaic Power Generation Expo in Japan (February 27 – 29). At the conference Mrs Tulloch will scope out the huge potential for DSC in each major solar market place and explain the characteristics of each market sector.

As this Expo is Dyesol’s major exhibition in East Asia for 2008, the Company will also be exhibiting - in association with its Japanese agent CCIC and collaborator Peccell - Dyesol’s full range of materials, products and selected equipments. Materials and applications experts will also be on hand to assist clients and visitors.

And while Mrs Tulloch is in Japan, fellow director Mr Gordon Thompson will deliver a keynote address on “Advantages for Dye Solar Cells for BIPV for Hot Climates “in Egypt.

At the Solar´08 ´´Putting Light to Work’ ‘conference in Cairo (24-28), Mr Thompson will explain how DSC works in low light conditions and why it is the most suitable photovoltaic for use on the facades of buildings. Most importantly, he will demonstrate how DSC can be engineered for optimum performance in the hot climates of the Mediterranean and Gulf regions and compare them to traditional solar cells which lose performance at high temperatures. In addition, performance and durability data will be provided to demonstrate the viability of DSC as Facade BIPV based on Dyesol’s 13 years experience in developing a proving DSC technology and products.

And at the International Conference on.Nanoscience and Nanotechnology (ICONN2008) in Melbourne on 25 – 29 February 2008, Dyesol is exhibiting its range of nanomaterials and equipment for nano-processing as well as presenting two papers.

Dyesol’s Chief Scientist Mr Hans Desilvestro, will outline price targets for all materials to achieve low cost DSC and explain how Dyesol has addressed these requirements while Chief Chemist Dr Andrew Koplick will discuss Dyesol’s titanium dioxide nano particle research, specifically for high speed application processes.

Convinced that 2008 would be the “break through’ year, Dyesol began an expansive expansion program in 2007.

The Company raised over $22.5 million to fund new manufacturing facilities, expand national and international infrastructure and fund strategically important acquisitions. In addition, Dyesol’s share register was strengthened by the addition of over 1000 new shareholders, including some of the most respected investors in international ‘clean tech’ stocks.

The global market for photovoltaic cells is growing by an average of 30 per cent annually and in 2006 was valued at US$15 billion.

Solar energy is already a major focus of governments throughout the world, particularly in Europe. Europe continues to be a major focus for Dyesol which opened an office in Singapore, acquired a subsidiary in Switzerland and launched a subsidiary in the United Kingdom in 2007.

Since listing in 2005, Dyesol has grown to a market capitalisation of more than $105 million and in the medium term, aims to be a $500 million company, doubling sales annually through strategic alliances to exploit its intellectual property.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.